RxDoctor Payments Data

Nancy Cho, MD

Cardiovascular Disease · Vero Beach, FLNPI 1942235015

Payments from drug & device makers

$8,449in general payments, 2019–2025

Across 290 payments — averaging $29.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$890
  • Novo Nordisk$733
  • GSK$709
  • Boston Scientific$590
  • AstraZeneca$523
  • Novartis$506
  • plus $4K from 36 others

What the payments were for

  • Consulting fees$200%
  • Food & beverage$8,32098%
  • Education$781%
  • Other$300%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,449 in reported general payments places this provider in the 70th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$134,993
Medicare patients
204
Services billed
2,841

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban222$263,594
OzempicSemaglutide122$148,335
JardianceEmpagliflozin104$108,093
MounjaroTirzepatide53$63,720
Repatha SureclickEvolocumab44$44,362
EntrestoSacubitril/Valsartan37$40,706
XareltoRivaroxaban39$38,333
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$30,711
FarxigaDapagliflozin Propanediol22$27,951
Praluent PenAlirocumab25$15,581
GemtesaVibegron15$15,017
NexletolBempedoic Acid23$13,676
Ezetimibe191$6,239
Eplerenone72$5,480
Colchicine31$4,467

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$137$263,594222 claims
Novo NordiskOzempic$733$148,335122 claims
Boehringer IngelheimJardiance$388$108,093104 claims
Lilly USA, LLCMounjaro$495$63,72053 claims
NovartisEntresto$506$40,70637 claims
Johnson & JohnsonXarelto$11$38,33339 claims
GSKTrelegy Ellipta$709$30,71129 claims
AstraZenecaFarxiga$523$27,95122 claims
Esperion Therapeutics, Inc.Nexletol$300$13,67623 claims
AbbVieSynthroid$14$3,26931 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Vero Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →